Zenas BioPharma has acquired 1 company, including 1 in the last 5 years.
Zenas BioPharma has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
1000 Winter St., North Building, Suite 1200,
Waltham, Massachusetts
02451
United States,
(857) 271-2954
www.zenasbio.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2021-11-11 |
Obexelimab · Life Science
Monrovia, California Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain and uses Xencor’s XmAb®Immune Inhibitor Fc Domain to target FcγRIIb, a receptor that inhibits the function of B-cells, which are important components in the immune system. Obexelimab is based in Monrovia, California. |
- | Divestiture |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
